UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   Oosthuizen Johannes Jacobus
   (Last) (First) (Middle)
   MERCK & CO., INC., 126 EAST LINCOLN AVENUE
   RAHWAY, NJ 07065

2. Issuer Name and Ticker or Trading Symbol
   Merck & Co., Inc. [ MRK ]

3. Date of Earliest Transaction (MM/DD/YYYY)
   10/30/2023

4. If Amendment, Date Original Filed (MM/DD/YYYY)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
   ___ Director
   ___ 10% Owner
   X Officer (give title below)
   ___ Other (specify below)
   President, U.S. Market

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security</th>
<th>2. Trans. Date</th>
<th>3A. Deemed Execution Date, if any</th>
<th>3. Trans. Code (Instr. 8)</th>
<th>4. Securities Acquired (A) / Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>10/30/2023</td>
<td>M</td>
<td>V 915 A</td>
<td>$102.82</td>
<td>20,722,657</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/30/2023</td>
<td>F</td>
<td>G 451 D</td>
<td>$102.82</td>
<td>20,271,657</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Unit</td>
<td>M</td>
<td>10/30/2023</td>
<td>M</td>
<td>915 A</td>
<td>10/30/2021 10/30/2023</td>
<td>Common Stock 915 $0 0 D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:
(1) Holdings include shares acquired in dividend reinvestment transactions.
(2) Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
(3) These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2021, 10/30/2022 and 10/30/2023.

Reporting Owners

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oosthuizen Johannes Jacobus</td>
<td>Director 10% Owner Officer President, U.S. Market</td>
</tr>
</tbody>
</table>

Signatures
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.